Targeted Strategies for Today's Evolving Markets

MissionIR Blog

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Offering to Include Boutique End-to-End CDMO Services

  • BiondVax’s CDMO services allow the company to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services
  • BiondVax showcased its boutique end-to-end CDMO offering at the annual Biomed Conference in Tel Aviv in May
  • BiondVax’s cGMP biologics manufacturing facility in Jerusalem is fully equipped with state-of-the-art CDMO capabilities
  • The expansion of CDMO services will augment revenue and expand pharma contacts while still maintaining BiondVax’s core focus of NanoAb therapies for significant indications like COVID-19, psoriasis, asthma, and more

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently showcased the expansion of its service to begin offering services as a contract development and manufacturing organization (“CDMO”). These CDMO services will allow BiondVax to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services, leveraging its Good Manufacturing Practices (“GMP”) biologics manufacturing facility in Jerusalem.

In May, BiondVax showcased its boutique end-to-end CDMO services and expertise at a leading conference for international Life Science and HealthTech industries, the Biomed Conference, in Tel Aviv. The company’s CDMO services are designed to meet the needs of pharmaceutical and biotechnology companies of all sizes, with a commitment to providing customers with the highest levels of quality and service.

BiondVax’s CDMO offers a comprehensive range of services and assets, including:

  • cGMP manufacturing of biologics at FDA and EMA standards
  • State-of-the-art laboratories for manufacturing process development and scale-up
  • Deep pharma experience and leadership to help accelerate products forward

The company’s cGMP manufacturing suites include clean rooms for upstream fermentation, downstream purification, labeling and visual inspection. It has previously passed the required audits for Phase 3 clinical trial production and more – which can be found in BiondVax’s CDMO literature. (

“Offering CDMO services allows us to use our state-of-the-art facility to generate revenues and offset certain fixed costs while still using it for our NanoAbs,” BiondVax CEO Amir Reichman said in a year-end letter to stakeholders. In a March interview, he also said his team has proven experience with running pre-clinical trials, clinical trials, chemistry, manufacturing and controls [CMC], quality assistance — with everything working like an oiled machine ( “Also, the capacity and the capabilities are there.”

BiondVax’s NanoAbs, also known as VHH-antibodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies. These advantages include stability at high temperatures, superior binding affinity, more effective and convenient routes of administration, and efficient production. The company is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

BiondVax’s development of NanoAb therapies addresses diseases that are currently underserved by current treatments, with large growing markets. In addition to COVID-19, the growing market outlook for asthma and psoriasis supports BiondVax’s focus on creating efficient therapies for patients in these indications.

Recent company statements on its quarterly financial results noted that it has already begun R&D activities for an innovative NanoAb platform targeting immune system cytokines. The drug candidate development process will focus on cytokines such as IL-17 for their potential in treating psoriasis and psoriatic arthritis.

Adding the CDMO services will keep the team abreast of the latest industry developments and trends while building experience and generating revenue to support the company’s NanoAb focus – targeting COVID-19, psoriasis, asthma, and more.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all

This entry was posted in BiondVax Pharmaceuticals Ltd. BVXV. Bookmark the permalink.

Comments are closed.